Is Little Green Pharma (ASX:LGP) Using Debt Sensibly?
Jan 17
Have your own idea? Try our Stock Screener
Australian (ASX) Pharma Industry Analysis
UpdatedJan 18, 2025
DataAggregated Company Financials
Companies29
- 7D3.0%
- 3M-16.0%
- 1Y-6.8%
- YTD1.3%
Over the last 7 days, the Pharma industry has risen 3.0%, driven by gains from Neuren Pharmaceuticals of 11%. Meanwhile, Neurizon Therapeutics actually underperformed within the industry, shrinking 18% in the last week. In contrast, the industry has lost 6.8% in the last 12 months. As for the next few years, earnings are expected to grow by 36% per annum.
Industry Valuation and Performance
Has the Australian Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 19 Jan 2025 | AU$5.3b | AU$1.0b | -AU$378,981,112.00 | 12.5x | -14.1x | 5.3x |
| Tue, 17 Dec 2024 | AU$5.5b | AU$1.0b | -AU$378,981,112.00 | 12x | -14.4x | 5.4x |
| Thu, 14 Nov 2024 | AU$6.7b | AU$1.0b | -AU$377,703,112.00 | 14.1x | -17.8x | 6.6x |
| Sat, 12 Oct 2024 | AU$6.4b | AU$1.0b | -AU$377,703,112.00 | 13.9x | -16.8x | 6.3x |
| Mon, 09 Sep 2024 | AU$6.3b | AU$1.0b | -AU$365,958,403.00 | 13.9x | -17.3x | 6.3x |
| Wed, 07 Aug 2024 | AU$6.1b | AU$995.3m | -AU$387,920,108.00 | 10.7x | -15.7x | 6.1x |
| Fri, 05 Jul 2024 | AU$6.3b | AU$995.3m | -AU$387,920,108.00 | 11.5x | -16.3x | 6.4x |
| Sun, 02 Jun 2024 | AU$6.6b | AU$1.2b | -AU$344,938,684.00 | 13.8x | -19.1x | 5.5x |
| Tue, 30 Apr 2024 | AU$5.5b | AU$1.2b | -AU$374,923,684.00 | 13.5x | -14.7x | 4.5x |
| Thu, 28 Mar 2024 | AU$5.8b | AU$1.2b | -AU$374,923,684.00 | 15.2x | -15.3x | 4.7x |
| Sat, 24 Feb 2024 | AU$5.4b | AU$897.1m | -AU$529,973,278.00 | 20.6x | -10.2x | 6x |
| Mon, 22 Jan 2024 | AU$5.7b | AU$896.3m | -AU$589,604,392.00 | 20.8x | -9.6x | 6.3x |
| Wed, 20 Dec 2023 | AU$5.5b | AU$896.3m | -AU$589,604,392.00 | 18.2x | -9.4x | 6.2x |
| Fri, 17 Nov 2023 | AU$4.1b | AU$893.0m | -AU$595,020,018.00 | 18.2x | -6.8x | 4.6x |
| Sun, 15 Oct 2023 | AU$3.5b | AU$900.3m | -AU$587,952,018.00 | 19.8x | -5.9x | 3.9x |
| Tue, 12 Sep 2023 | AU$3.7b | AU$900.3m | -AU$587,952,018.00 | 19.3x | -6.3x | 4.1x |
| Thu, 10 Aug 2023 | AU$4.0b | AU$999.0m | -AU$624,794,303.00 | 20.6x | -6.4x | 4x |
| Sat, 08 Jul 2023 | AU$4.0b | AU$999.0m | -AU$624,794,303.00 | 24.5x | -6.5x | 4x |
| Mon, 05 Jun 2023 | AU$4.1b | AU$999.0m | -AU$624,794,303.00 | 20.4x | -6.5x | 4.1x |
| Wed, 03 May 2023 | AU$4.2b | AU$993.2m | -AU$641,969,868.00 | 21.3x | -6.6x | 4.2x |
| Fri, 31 Mar 2023 | AU$4.2b | AU$995.9m | -AU$648,651,745.00 | 19.3x | -6.4x | 4.2x |
| Sun, 26 Feb 2023 | AU$3.6b | AU$1.0b | -AU$596,563,139.00 | 17.9x | -6x | 3.4x |
| Tue, 24 Jan 2023 | AU$4.0b | AU$951.8m | -AU$584,038,383.00 | 17.5x | -6.8x | 4.2x |
| Thu, 22 Dec 2022 | AU$3.8b | AU$948.3m | -AU$544,428,006.00 | 13.2x | -7x | 4x |
| Sat, 19 Nov 2022 | AU$4.4b | AU$948.3m | -AU$544,428,005.00 | 12.9x | -8x | 4.6x |
| Mon, 17 Oct 2022 | AU$4.2b | AU$946.2m | -AU$548,400,005.00 | 12x | -7.7x | 4.5x |
| Wed, 14 Sep 2022 | AU$4.2b | AU$943.4m | -AU$537,548,829.00 | 12.7x | -7.8x | 4.5x |
| Fri, 12 Aug 2022 | AU$4.2b | AU$819.9m | -AU$339,669,589.00 | 15.6x | -12.3x | 5.1x |
| Sun, 10 Jul 2022 | AU$3.5b | AU$818.2m | -AU$353,932,589.00 | 14.6x | -9.8x | 4.2x |
| Tue, 07 Jun 2022 | AU$3.8b | AU$818.2m | -AU$353,932,589.00 | 14.3x | -10.7x | 4.6x |
| Thu, 05 May 2022 | AU$3.9b | AU$800.9m | -AU$348,637,558.00 | 14.7x | -11.1x | 4.8x |
| Sat, 02 Apr 2022 | AU$4.2b | AU$799.2m | -AU$341,805,125.00 | 18.2x | -12.3x | 5.3x |
| Mon, 28 Feb 2022 | AU$4.3b | AU$793.6m | -AU$326,255,170.00 | 18.1x | -13.3x | 5.5x |
| Wed, 26 Jan 2022 | AU$4.4b | AU$758.4m | -AU$450,516,414.00 | 19.1x | -9.7x | 5.8x |
Price to Earnings Ratio
-9.7x
Current Industry PE
- Investors are relatively neutral on the Australian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 5.0x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
- Revenues for these companies have grown 10% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Trends
Which industries have driven the changes within the Australian Healthcare industry?
| AU Market | 0.099% | |
| Healthcare | -2.45% | |
| Pharma | 2.96% | |
| Pharma | 2.96% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| NEU Neuren Pharmaceuticals | AU$13.20 | 10.8% +AU$163.8m | -43.4% | PE14.3x | |
| CU6 Clarity Pharmaceuticals | AU$3.94 | 1.8% +AU$22.5m | 67.7% | PS109.8x | |
| ALA Arovella Therapeutics | AU$0.19 | 2.7% +AU$5.3m | 40.7% | PS103.1x | |
| SPL Starpharma Holdings | AU$0.12 | 9.1% +AU$4.2m | -25.0% | PS5.1x | |
| LTP LTR Pharma | AU$0.74 | 2.8% +AU$3.6m | 146.7% | PS2733x |